Blocking lipid signaling to treat advanced, hormone‑resistant prostate cancer
Targeting Castration Resistant Prostate Cancer via Potent Inhibition of Signaling Lipids
This project aims to block lipid signaling with potent inhibitors to help men whose prostate cancer no longer responds to hormone therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11170557 on NIH RePORTER |
What this research studies
You have advanced castration‑resistant prostate cancer that keeps growing despite hormone treatments; this research targets the fats and signaling pathways cancer cells use to survive. The team is developing and testing strong inhibitors of signaling lipids and the enzymes and transcription factors (like SREBP and PI3K/Akt) that drive lipid production in tumors. Work includes laboratory and animal studies and analysis of human tumor biology, with attention to differences seen in African American patients. The goal is to find approaches that could be turned into new treatments for patients whose cancers are currently lethal.
Who could benefit from this research
Good fit: Men with metastatic castration‑resistant prostate cancer who have progressed on standard hormone therapies would be the main candidates for related clinical efforts.
Not a fit: People with early‑stage prostate cancer, women, or tumors that do not rely on lipid signaling pathways are unlikely to benefit from this work.
Why it matters
Potential benefit: If successful, this could slow or stop growth of hormone‑resistant prostate tumors and lead to new treatment options for men with metastatic CRPC.
How similar studies have performed: Preclinical studies targeting lipid metabolism and PI3K/Akt pathways have slowed tumor growth in models, but clinical therapies based on this approach are still emerging.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Kaochar, Salma — Baylor College of Medicine
- Study coordinator: Kaochar, Salma
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.